Stockscreener 앱 받기
3.085
0.16%
-0.005
시간 외 거래:
2.99
-0.095
-3.08%
Inmed Pharmaceuticals Inc 주식(INM)의 최신 뉴스
SEC Form PRE 14A filed by InMed Pharmaceuticals Inc. - Quantisnow
InMed Pharmaceuticals cancels special shareholder meeting By Investing.com - Investing.com Canada
InMed Pharmaceuticals cancels special shareholder meeting - Investing.com
InMed Pharmaceuticals sets date for special shareholder meeting By Investing.com - Investing.com South Africa
InMed Pharmaceuticals sets date for special shareholder meeting - Investing.com
InMed Pharmaceuticals stock hits 52-week low at $1.72 - Investing.com Australia
InMed Pharmaceuticals stock hits 52-week low at $1.72 By Investing.com - Investing.com South Africa
InMed Pharmaceuticals : Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview - MarketScreener
InMed Pharmaceuticals Stock Hits 52-Week Low at $2.34 By Investing.com - Investing.com India
InMed Pharmaceuticals Stock Hits 52-Week Low at $2.34 - Investing.com India
InMed Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
InMed Pharmaceuticals Struggles with Losses Amid Revenue Decline - MSN
InMed Pharmaceuticals Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Defense World
InMed Pharmaceuticals Board Reshuffle After Director Resignation - TipRanks
InMed Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Yahoo Finance
InMed Pharmaceuticals Inc. (INM) reports earnings - Quartz
InMed Pharmaceuticals Inc. SEC 10-Q Report - TradingView
InMed Advances INM-089 for Dry AMD Treatment with New Intravitreal Formulation - TipRanks
Inmed selects IVT formulation of INM-089 for dry AMD - BioWorld Online
InMed advances AMD treatment with promising IVT drug formulation - MSN
Revolutionary Eye Drug INM-089 Achieves 10X Therapeutic Levels in Macular Degeneration Treatment - StockTitan
Inmed Pharmaceuticals Inc (INM-Q) QuotePress Release - The Globe and Mail
InMed Pharmaceuticals (NASDAQ: INM) Secures International Patent for Novel Compounds - Defense World
InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs - TipRanks
InMed Pharmaceuticals secures international patent - Investing.com India
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds - Newsfile
InMed Secures Breakthrough 20-Year Patent in Mexico for Novel Cannabinoid Compounds - StockTitan
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise - Asianet Newsable
InMed Pharmaceuticals (NASDAQ: INM) Announces Positive Results from INM-901 Alzheimer’s Disease Study - Defense World
InMed Hails Alzheimer's Study, Stocks Shoot Higher - Baystreet.ca
InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study - TipRanks
InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study - TipRanks
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study - Newsfile
SABBY MANAGEMENT, LLC Acquires Shares in InMed Pharmaceuticals I - GuruFocus
InMed Pharmaceuticals Inc. Holds 2024 Annual General Meeting – Elects Directors and Appoints Auditor - Defense World
InMed Pharmaceuticals Director Faces Resignation After Shareholder Vote at Annual Meeting - StockTitan
InMed Announces Results of 2024 Annual General Meeting - Newsfile
InMed Pharmaceuticals Inc. announced that it expects to receive CAD 10 million in funding - Marketscreener.com
InMed Enters Into Standby Equity Purchase Agreement - Newsfile
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
3.92%
자본화:
|
볼륨(24시간):